Literature DB >> 35325245

Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.

Anna F Piotrowski1, Sadhana Jackson2.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 35325245      PMCID: PMC9340616          DOI: 10.1093/neuonc/noac081

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  11 in total

1.  A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.

Authors:  Saba Sharif; Meena Upadhyaya; Rosalie Ferner; Elisa Majounie; Andrew Shenton; Michael Baser; Nalin Thakker; D Gareth Evans
Journal:  J Med Genet       Date:  2011-01-28       Impact factor: 6.318

2.  Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.

Authors:  Michael J Fisher; Michael Loguidice; David H Gutmann; Robert Listernick; Rosalie E Ferner; Nicole J Ullrich; Roger J Packer; Uri Tabori; Robert O Hoffman; Simone L Ardern-Holmes; Trent R Hummel; Darren R Hargrave; Eric Bouffet; Joel Charrow; Larissa T Bilaniuk; Laura J Balcer; Grant T Liu
Journal:  Neuro Oncol       Date:  2012-04-03       Impact factor: 12.300

3.  Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1).

Authors:  Michael J Fisher; David T W Jones; Stefan M Pfister; David H Gutmann; Yimei Li; Xiaofan Guo; Poonam S Sonawane; Angela J Waanders; Joanna J Phillips; William A Weiss; Adam C Resnick; Sara Gosline; Jineta Banerjee; Justin Guinney; Astrid Gnekow; Daniela Kandels; Nicholas K Foreman; Andrey Korshunov; Marina Ryzhova; Luca Massimi; Sri Gururangan; Mark W Kieran; Zhihong Wang; Maryam Fouladi; Mariko Sato; Ingrid Øra; Stefan Holm; Stephen J Markham; Pengbo Beck; Natalie Jäger; Andrea Wittmann; Alexander C Sommerkamp; Felix Sahm
Journal:  Acta Neuropathol       Date:  2021-02-14       Impact factor: 17.088

4.  Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.

Authors:  Chelsea Kotch; Robert Avery; Kelly D Getz; Eric Bouffet; Peter de Blank; Robert Listernick; David H Gutmann; Miriam Bornhorst; Cynthia Campen; Grant T Liu; Richard Aplenc; Yimei Li; Michael J Fisher
Journal:  Neuro Oncol       Date:  2022-08-01       Impact factor: 13.029

5.  Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.

Authors:  Alvaro Lassaletta; Katrin Scheinemann; Shayna M Zelcer; Juliette Hukin; Beverley A Wilson; Nada Jabado; Anne Sophie Carret; Lucie Lafay-Cousin; Valerie Larouche; Cynthia E Hawkins; Gregory Russell Pond; Ken Poskitt; Daniel Keene; Donna L Johnston; David D Eisenstat; Rahul Krishnatry; Matthew Mistry; Anthony Arnoldo; Vijay Ramaswamy; Annie Huang; Ute Bartels; Uri Tabori; Eric Bouffet
Journal:  J Clin Oncol       Date:  2016-10-10       Impact factor: 44.544

6.  Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood.

Authors:  R J Packer; B Lange; J Ater; H S Nicholson; J Allen; R Walker; M Prados; R Jakacki; G Reaman; M N Needles
Journal:  J Clin Oncol       Date:  1993-05       Impact factor: 44.544

Review 7.  Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.

Authors:  Reinhard E Friedrich; Michael A Nuding
Journal:  Anticancer Res       Date:  2016-08       Impact factor: 2.480

8.  Natural history and outcome of optic pathway gliomas in children.

Authors:  Gary Nicolin; Patricia Parkin; Donald Mabbott; Darren Hargrave; Ute Bartels; Uri Tabori; James Rutka; J Raymond Buncic; Eric Bouffet
Journal:  Pediatr Blood Cancer       Date:  2009-12-15       Impact factor: 3.167

9.  Functional outcome measures for NF1-associated optic pathway glioma clinical trials.

Authors:  Michael J Fisher; Robert A Avery; Jeffrey C Allen; Simone L Ardern-Holmes; Larissa T Bilaniuk; Rosalie E Ferner; David H Gutmann; Robert Listernick; Staci Martin; Nicole J Ullrich; Grant T Liu
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

10.  NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat.

Authors:  Amedeo A Azizi; David A Walker; Jo-Fen Liu; Astrid Sehested; Timothy Jaspan; Berthold Pemp; Ian Simmons; Rosalie Ferner; Jacques Grill; Darren Hargrave; Pablo Hernáiz Driever; D Gareth Evans; Enrico Opocher
Journal:  Neuro Oncol       Date:  2021-01-30       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.